(Q44193696)

30 November 2017

title

A pilot study of beta-interferon for treatment of patients with chronic hepatitis B who failed to respond to alpha-interferon (English)

1 reference

30 November 2017

1 reference

Raquel Muñoz

1

1 reference

30 November 2017

Gregorio Castellano

2

1 reference

30 November 2017

Inmaculada Fernández

3

1 reference

30 November 2017

Maria Victoria Alvarez

4

1 reference

30 November 2017

Maria Luisa Manzano

5

1 reference

30 November 2017

Maria Soledad Marcos

6

1 reference

30 November 2017

Beatriz Cuenca

7

1 reference

30 November 2017

José A Solís-Herruzo

8

1 reference

30 November 2017

language of work or name

1 reference

1 November 2002

1 reference

30 November 2017

published in

Journal of Hepatology

1 reference

30 November 2017

volume

37

1 reference

30 November 2017

issue

5

1 reference

30 November 2017

page(s)

655-659

1 reference

Survival in chronic hepatitis B. An analysis of 379 patients

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

Antiviral chemotherapy for the treatment of hepatitis B virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

Failure of acyclovir to enhance the antiviral effect of alpha lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B. A multi-centre randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

Interferon-alpha and zidovudine combination therapy for chronic hepatitis B: results of a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

Pilot study of ribavirin and interferon-beta for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

Repeated courses of alpha-interferon for treatment of chronic hepatitis type B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

1 reference

7 January 2021

What is new in the treatment of multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

Pilot interferon-beta trial in children with chronic hepatitis B who had previously not responded to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

Classification of chronic viral hepatitis: a need for reassessment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900261-1

7 January 2021

10.1016/S0168-8278(02)00261-1

Identifiers

DOI

1 reference

30 November 2017

1 reference